Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amgen, Inc. (AMGN) vs Chewy Inc (CHWY) Price & Performance

Amgen, Inc.Trade

Price performance (Past 24H)

Key statistics

Amgen, Inc. vs Chewy Inc — how do they compare? Amgen, Inc. trades at $415.16 (market cap $224.14B), while Chewy Inc trades at $22.12 (market cap $9.20B). The key difference: Amgen, Inc. is far larger — about 24.4× Chewy Inc's market cap, and Amgen, Inc. pays a 2.43% dividend while Chewy Inc pays none. Which is the better fit depends on your goals.

AMGNCHWY
Market Cap
$224.14B$9.20B
Sector
HealthConsumer Cyclical
52-Week High
$417.20$42.33
52-Week Low
$271.18$17.51
Enterprise Value
$267.45B$9.16B
Dividend Yield
2.43%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amgen, Inc.

Amgen (AMGN) trades at $416.74, showing minimal daily movement with a slight 0.11% decline. The stock maintains strong technical momentum with bullish moving averages and support at $412. Fundamentally, the company demonstrates robust performance with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, while revenue growth continues with 2025 revenue reaching $36.75 billion. Analyst sentiment remains positive with 59% buy ratings, though the current price exceeds the consensus target of $394.69.

Amgen presents a mixed outlook with strong earnings momentum and product growth offset by valuation concerns. Investment opportunities include continued blockbuster drug performance and raised 2026 guidance, while risks involve high debt levels and potential data breach litigation impacts. The stock's current premium valuation requires sustained execution to justify further upside.

Chewy Inc

Chewy (CHWY) trades at $22.16, down 1.9% on the day, with a bearish technical signal from moving averages but neutral oscillators. Revenue grew to $11.86B in 2025, with net income surging to $392.74M, though the net margin remains thin at 1.99%. Recent news highlights insider sales and institutional position changes, while analyst consensus remains strongly bullish with an 81.58% buy rating and a $33.82 price target.

The outlook is mixed: strong revenue growth and high ROE support upside potential, but thin margins, competitive pressures, and recent insider selling pose risks. Earnings beats in recent quarters provide momentum, yet the stock faces volatility near key support at $22. Investors should weigh robust analyst optimism against execution challenges in the pet care market.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amgen, Inc.

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).

Read more on AMGN

About Chewy Inc

Chewy is the largest e-commerce pet care retailer in the U.S., generating $8.9 billion in 2021 sales across pet food, treats, hard goods, and pharmacy categories. The firm was founded in 2011, acquired by PetSmart in 2017, and tapped public markets as a standalone company in 2019, after spending a couple of years developing under the aegis of the pet superstore chain. The firm generates sales from pet food, treats, over-the-counter medications, medical prescription fulfillment, and hard goods, like crates, leashes, and bowls.

Read more on CHWY